Clinical manifestation and survival of patients with small-cell lung cancer

Journal of the Medical Association of Thailand

Volumn 90, Issue 7, 2007, Pages 1303-1308

  Thammakumpee, Kreetha ^a   Juthong, Siwasak ^a   Viriyachaiyo, Vilaiwan ^a   Rittirak, Warangkana ^a   Tanomkiat, Wiwatana ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Prognosis; Small cell lung cancer; Treatment

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOLOGY; DYSPNEA; FEMALE; HISTOPATHOLOGY; HOARSENESS; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; REMISSION; SUPERIOR CAVA VEIN SYNDROME; DISEASE COURSE; MIDDLE AGED; MORTALITY; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDY; SMALL CELL CARCINOMA; SURVIVAL; THAILAND;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THAILAND;

EID: 34548525924     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Sriplung H, Sontipong S, Martin N, Wiangnon S, Vootiprux V, Cheirsilpa A, et al. Cancer incidence in Thailand, 1995-1997. Asian Pac J Cancer Prev 2005; 6: 276-81.
2. Vatanasapt V, Martin N, Sriplung H, Chindavijak K, Sontipong S, Sriamporn H, et al. Cancer incidence in Thailand, 1988-1991. Cancer Epidemiol Biomarkers Prev 1995; 4: 475-83.
3. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999; 17: 1794-801.
4. Hansen HH. Management of small-cell cancer of the lung. Lancet 1992; 339: 846-9.
5. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855-61.
6. Abrams J, Doyle LA, Aisner J. Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol 1988; 15: 261-77.
7. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
8. Wongthim S, Udompanich V, Limthongkul S, Charoenlap P, Nuchprayoon C, Thitathan S. Small cell lung cancer in Chulalongkorn Hospital. Chula Med J 1988; 32: 129-35.
9. Campling BG, Sarda IR, Baer KA, Pang SC, Baker HM, Lofters WS, et al. Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer. Cancer 1995; 75: 2442-51.
10. Shepherd FA, Laskey J, Evans WK, Goss PE, Johansen E, Khamsi F. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol 1992; 10: 21-7.
11. Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004; 49: 119-33.
12. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20: 4665-72.
13. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327: 1618-24.
14. Thammakumpee K. Clinical manifestation and survival of patients with non-small cell lung cancer. J Med Assoc Thai 2004; 87: 503-7.